Markets had priced in months of good news all at once.
In the long rhythm of currency markets, a currency that rises swiftly must sometimes pause to catch its breath. Sterling, having ridden Britain's vaccine momentum to its best quarter against the euro since 2015, retreated sharply this week as supply disruptions slowed the UK's inoculation campaign and Europe's own rollout gathered pace. The pound's 1.8 percent weekly decline against the euro — its steepest since September 2020 — was less a verdict on Britain's recovery than a market exhaling after months of optimism, with most analysts still expecting the underlying story to reassert itself in time.
- Sterling touched a two-month low against the dollar and suffered its worst weekly loss against the euro since September 2020, erasing a significant portion of its remarkable first-quarter gains.
- Oxford-AstraZeneca supply disruptions slowed Britain's vaccination pace just as Germany and the broader EU accelerated their own rollouts, unsettling the core assumption that had driven sterling higher all winter.
- A technical short squeeze — investors forced to unwind bets against the euro-pound pair — amplified the selling pressure across Tuesday, Wednesday, and Thursday, turning a correction into a rout.
- By Friday, the pound had steadied near 86.5 pence per euro and $1.3733 against the dollar, but the damage for the week was done and the direction of travel had visibly shifted.
- Major institutions including UBS, ING, and UniCredit held their bullish long-term positions, framing the pullback as a profit-taking pause rather than a fundamental reversal of sterling's recovery story.
The pound endured a bruising week. By Friday morning in London, sterling had fallen to its lowest point against the dollar in two months, and the weekly loss against the euro — 1.8 percent — was the sharpest since September 2020. The currency found some footing as the day progressed, but the broader arc was one of retreat.
The reversal was striking given how strong the preceding months had been. Sterling had just completed its best quarter against the euro since 2015, lifted by Britain's world-leading vaccine rollout, near-50 percent first-dose coverage, and widespread confidence that the UK economy would outpace the eurozone in recovery. Interest rate expectations had also tilted in the pound's favor, pushing it steadily higher through winter and into spring.
This week, that momentum broke. Three consecutive days of losses against the euro were partly driven by a technical short squeeze, as traders who had bet against the euro-pound pair were forced to cover their positions, magnifying the move. Underlying the shift was a change in vaccine optics: supply problems with the Oxford-AstraZeneca shot had slowed Britain's rollout, while Germany and the EU were accelerating theirs. Analysts at BDSwiss described the selling as a recalibration of relative optimism.
Not everyone had turned cautious. Economists at UBS maintained that sterling remained undervalued and forecast the euro-pound pair would fall below 0.85 before year's end. ING believed the short squeeze had run its course. UniCredit called the dip toward $1.37 against the dollar a buying opportunity. The consensus among bulls was that the fundamental case — faster UK recovery, vaccine advantage, favorable rate differentials — remained intact. Markets, having priced in months of good news, were simply pausing to take profits.
The pound had a rough week. By Friday morning in London, sterling had already touched its lowest point against the dollar in two months, and the damage against the euro was worse—a weekly decline of 1.8 percent, the steepest fall since September 2020. The currency steadied somewhat as the day wore on, but the broader picture was one of retreat after months of gains.
Just three months earlier, sterling had enjoyed its best quarter against the euro since 2015. The reasons were straightforward: Britain's vaccine rollout was among the fastest in the world, nearly half the population had received a first dose, and investors believed the UK economy would recover faster than the eurozone. Interest rate expectations had also shifted in sterling's favor. All of this had pushed the pound higher through the winter and into spring.
But this week, the momentum reversed sharply. On Tuesday, Wednesday, and Thursday, sterling fell against the euro three days running. Market participants attributed much of the selling to what traders call a short squeeze—a technical phenomenon where investors who had bet against the euro-pound pair were forced to cover their positions, amplifying the move. The pound finished Friday at 86.565 pence per euro, up slightly on the day but deeply underwater for the week. Against the dollar, it held near $1.3733, also tracking toward a weekly loss.
The shift reflected changing perceptions about vaccination momentum. Supply problems with the Oxford-AstraZeneca vaccine, Britain's workhorse shot, had slowed the UK's inoculation campaign in recent days. Meanwhile, Germany and the broader European Union had accelerated their rollout. Marshall Gittler, head of investment research at BDSwiss, suggested the selling reflected a recalibration: investors were becoming more optimistic about the EU's vaccine progress and less confident about Britain's ability to maintain its edge.
Yet not all analysts had turned bearish. Dean Turner, chief eurozone and UK economist at UBS Global Wealth Management, maintained that sterling remained undervalued and predicted the euro-pound pair could fall below 0.85 before year's end—meaning sterling would strengthen further. ING echoed that view, arguing the short squeeze had likely run its course and that the pair would eventually reach 0.85 in the coming quarter. UniCredit strategists saw the pound's recent weakness against the dollar as a buying opportunity, suggesting the decline toward $1.37 was temporary.
The week's reversal, then, was less a fundamental shift in sterling's prospects than a correction after a powerful run. The underlying economic story—Britain's faster recovery, its vaccine advantage, the interest rate differential—remained intact. But markets, having priced in months of good news, were taking profits. How long that pause would last remained an open question.
Citações Notáveis
The selling of sterling may have been connected to buying of euros, as people grew more optimistic about the EU's vaccine rollout and less optimistic about the UK's comparable progress.— Marshall Gittler, head of investment research at BDSwiss
Sterling remains an undervalued currency, and the euro-pound pair could fall below 0.85 this year.— Dean Turner, chief eurozone and UK economist at UBS Global Wealth Management
A Conversa do Hearth Outra perspectiva sobre a história
Why did sterling fall so sharply this week when the UK's vaccine rollout was still ahead of Europe's?
Because markets had already priced in that advantage over the first quarter. Once you've made your gains, you take them. The selling wasn't really about the UK getting worse—it was about the EU getting better, faster than expected.
So the Oxford-AstraZeneca supply issues were just the excuse?
Not just an excuse. They were real. But they mattered more psychologically than fundamentally. The UK was still ahead; it just wasn't pulling away anymore. That's enough to flip sentiment.
What's a short squeeze in this context?
Traders had bet the pound would weaken. When it didn't, they had to buy it back to close those bets. That buying pressure itself pushed the pound down further, creating a self-reinforcing move. It's mechanical, not rational.
Do the analysts think this is the end of sterling's strength?
No. Most still expect it to rise further. They see this as a pause, maybe even a chance to buy cheaper. The economic fundamentals—faster UK growth, better rates—haven't changed.
So what should someone watching this market be looking for?
Watch the vaccination numbers. If the UK's lead widens again, sterling will likely recover. If the EU keeps closing the gap, there's more downside risk. The currency is really just a referendum on whose economy recovers first.